Future preclinical studies could move towards the application of diurnal models with conserved circadian clock architecture, ideally bearing tumours with defined clock phenotypes, ranging from functional to disrupted, and adopt more clinically relevant chronomodulated treatment protocols, such as prolonged low-dose intravenous anthracycline administration. Here, CLOCK is linked to neoplasm.